{"id":"NCT04615923","sponsor":"Merit E. Cudkowicz, MD","briefTitle":"HEALEY ALS Platform Trial - Regimen D Pridopidine","officialTitle":"HEALEY ALS Platform Trial - Regimen D Pridopidine","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2020-12-18","primaryCompletion":"2022-07-14","completion":"2022-07-14","firstPosted":"2020-11-04","resultsPosted":"2023-08-23","lastUpdate":"2023-08-23"},"enrollment":163,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Amyotrophic Lateral Sclerosis"],"interventions":[{"type":"DRUG","name":"Pridopidine","otherNames":[]},{"type":"DRUG","name":"Matching Placebo","otherNames":[]}],"arms":[{"label":"Pridopidine","type":"EXPERIMENTAL"},{"label":"Matching Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.\n\nRegimen D will evaluate the safety and efficacy of a single study drug, pridopidine, in participants with ALS.","primaryOutcome":{"measure":"Disease Progression as Assessed by the ALSFRS-R Total Score","timeFrame":"Baseline to 24 Weeks","effectByArm":[{"arm":"Pridopidine","deltaMin":-0.99,"sd":0.077},{"arm":"Matching Placebo","deltaMin":-1,"sd":0.07}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["40067755"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":121},"commonTop":["Fall","Muscular weakness","Neuromyopathy","Constipation","Diarrhoea"]}}